☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
UCB
UCB Reports the US FDA’s Acceptance of sBLA for Bimzelx (bimekizumab-bkzx) to Treat Hidradenitis Suppurativa
April 5, 2024
UCB’s Bimzelx Receives CHMP’s Positive Opinion to Treat Moderate to Severe Hidradenitis Suppurativa
March 22, 2024
UCB Receives the EC’s Approval for Rystiggo (rozanolixizumab) for the Treatment of Adults with Generalized Myasthenia Gravis (gMG)
January 8, 2024
UCB’s Zilbrysq (zilucoplan) Receives Approval from the EC to Treat Generalized Myasthenia Gravis (gMG)
December 4, 2023
UCB Reports the Results for Nayzilam in P-III Trial for the Treatment of Epilepsy
November 1, 2023
UCB’ Bimzelx (bimekizumab) Receives the US FDA’s Approval for the Treatment of Adults with Moderate to Severe Plaque Psoriasis
October 19, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.